Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11891931 | 0.85 | HPGDS (0.46) | AOC3HDAC6HDAC1HDAC8 | |
| SCHEMBL31375480 | 0.84 | AOC3 (0.47) | AOC3HDAC4HDAC6HDAC1HDAC8 | |
| SCHEMBL8360856 | 0.84 | HDAC6 (0.60) | HDAC4HDAC6HDAC1HDAC8 | |
| SCHEMBL8362557 | 0.84 | NOTUM (0.47) | HDAC4HDAC6NOTUMHDAC1HDAC8 | |
| Bromide SCHEMBL29373726 | 0.83 | HDAC6 (0.59) | HDAC4HDAC6HDAC1HDAC8 | |
| Hydrochloric Acid SCHEMBL18422626 | 0.83 | HDAC6 (0.59) | HDAC4HDAC6HDAC1HDAC8 | |
| SCHEMBL6497959 | 0.81 | AOC3 (0.50) | AOC3HDAC4HDAC6NOTUMKDM4E | |
| SCHEMBL6650093 | 0.81 | HDAC6 (0.50) | HDAC4HDAC6HDAC1HDAC8 | |
| SCHEMBL29974996 | 0.81 | HDAC6 (0.48) | HDAC4HDAC6NOTUMHDAC1HDAC8 | |
| Hydrochloric Acid SCHEMBL29975570 | 0.80 | HDAC6 (0.47) | HDAC4HDAC6NOTUMHDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486255-B2 | Modulators of RAS GTPase | TOSK, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20240279206-A1 | Modulators of RAS GTPase | TOSK, INC. | 2024-08-22 | — | — | US | disclosed |
| US-11945803-B2 | Modulators of RAS GTPase | TOSK, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| WO-2020033413-A2 | MODULATORS OF RAS GTPASE | TOSK, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486255-B2 | Modulators of RAS GTPase | KRAS, HRAS, NRAS | AOC3 4849/4885HDAC4 1731/4885HDAC6 785/4885 |
| US-11945803-B2 | Modulators of RAS GTPase | KRAS, HRAS, NRAS | AOC3 4849/4885HDAC4 1731/4885HDAC6 785/4885 |
| US-20240279206-A1 | Modulators of RAS GTPase | KRAS, HRAS, NRAS | AOC3 4849/4885HDAC4 1731/4885HDAC6 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.